An elevation of stem cell factor in patients with hyperthyroid Graves' disease

Area of Science:

• Endocrinology
• Immunology
• Hematology

Background:

• Graves' disease is an autoimmune disorder involving antibodies against the thyrotropin receptor (TRAb).
• Stem cell factor (SCF) from bone marrow influences lymphohematopoiesis.
• The relationship between SCF, thyroid hormones, and TRAb in Graves' disease requires investigation.

Purpose of the Study:

• To investigate the association between plasma SCF levels, thyroid hormone status, and TRAb in Graves' disease patients.
• To compare SCF levels across different stages of Graves' disease and other thyroid conditions.

Main Methods:

• Assessed plasma SCF levels, serum thyroxine (T4), triiodothyronine, and TRAb (measured by TBI) in various patient groups.
• Included untreated, treated, and relapsed hyperthyroid Graves' disease patients, Hashimoto's thyroiditis, subacute thyroiditis, and controls.

Main Results:

• Elevated plasma SCF levels were observed in untreated hyperthyroid Graves' disease patients and decreased with methimazole treatment.
• Plasma SCF levels correlated curvilinearly with serum T4 levels.
• Relapsed Graves' disease patients showed elevated SCF despite low or negative TBI.
• SCF levels were not significantly different from controls in subacute thyroiditis and Hashimoto's thyroiditis.

Conclusions:

• Elevated plasma SCF is associated with the longstanding thyrotoxic state in Graves' disease.
• Short-term thyrotoxicosis does not significantly impact plasma SCF levels.
• Further research is needed to determine if SCF elevation is caused by excess thyroid hormone or contributes to TRAb production.